RXRX
RECURSION PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.61
+4.18%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 40.49x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.36x
- Price / sales
- 39.34x
- Price / cash flow
- -6.16x
Enterprise value
- Enterprise value
- $1.7B
- EV / sales
- 30.52x
- EV / EBITDA
- -3.77x
- EV / EBIT
- -3.08x
- Market cap
- $2.2B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026